Literature DB >> 15362720

Transient focal ischemia affects the cAMP second messenger system and coupled dopamine D1 and 5-HT1A receptors in the living monkey brain: a positron emission tomography study using microdialysis.

Hideo Tsukada1, Dai Fukumoto, Shingo Nishiyama, Kengo Sato, Takeharu Kakiuchi.   

Abstract

Using positron emission tomography (PET) and microdialysis, the present study showed that neuronal damages after transient focal ischemia was partly induced by hyperactivation of the cyclic adenosine 3',5'-monophosphate (cAMP) second messenger system through modulations of dopamine D, and serotonin 5-HT1A receptors in the living brains of cynomolgus monkeys. Occlusion of the right middle cerebral artery for 3 hours suppressed CBF in the striatum, and reperfusion induced hyperperfusion in the neocortex and striatum of the occluded side. Six hours after reperfusion, the activity of the cAMP second messenger system assayed with [11C]rolipram was significantly facilitated in the neocortex and striatum where CBF was lowered more than 40% of normal during occlusion ("ischemic" area). Seven days later, impaired dopamine D1 and 5-HT1A receptor binding, measured with [11C]SCH23390 and [carbonyl-11C]WAY-100635, respectively, was observed in the ischemic area. Microdialysis analysis revealed that the striatal dopamine level provided a transient and marked increased during occlusion and after reperfusion, whereas the cortical serotonin level transiently increased only after reperfusion, and was at an undetectable level thereafter. Administration of rolipram (0.1 and 1 mg/kg, intravenously) during occlusion facilitated reduction of dopamine D1 binding, whereas rolipram administration 6 hours after reperfusion induced a further decrease in 5-HT1A receptor binding. These results suggest that the activation of cAMP second messenger system modulated by dopamine D1 and 5-HT1A receptors could be involved in the neuronal degeneration after transient cerebral ischemic insult.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15362720     DOI: 10.1097/01.WCB.0000126974.07553.86

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  8 in total

1.  Analysis of (R)- and (S)-[(11)C]rolipram kinetics in canine myocardium for the evaluation of phosphodiesterase-4 with PET.

Authors:  Mireille Lortie; Jean N DaSilva; Miran Kenk; Stephanie Thorn; Darryl Davis; David Birnie; Rob S B Beanlands; Robert A deKemp
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

Review 2.  Executive (dys)function after stroke: special considerations for behavioral pharmacology.

Authors:  Jessica M Povroznik; Jenny E Ozga; Cole Vonder Haar; Elizabeth B Engler-Chiurazzi
Journal:  Behav Pharmacol       Date:  2018-10       Impact factor: 2.293

3.  PDE4 regulates tissue plasminogen activator expression of human brain microvascular endothelial cells.

Authors:  Fan Yang; Shuo Liu; Chuanhui Yu; Shur-Jen Wang; Annlia Paganini-Hill; Mark J Fisher
Journal:  Thromb Res       Date:  2012-01-13       Impact factor: 3.944

4.  PET imaging of ischemia-induced impairment of mitochondrial complex I function in monkey brain.

Authors:  Hideo Tsukada; Hiroyuki Ohba; Shingo Nishiyama; Masakatsu Kanazawa; Takeharu Kakiuchi; Norihiro Harada
Journal:  J Cereb Blood Flow Metab       Date:  2014-01-22       Impact factor: 6.200

5.  Subanesthetic doses of ketamine transiently decrease serotonin transporter activity: a PET study in conscious monkeys.

Authors:  Shigeyuki Yamamoto; Hiroyuki Ohba; Shingo Nishiyama; Norihiro Harada; Takeharu Kakiuchi; Hideo Tsukada; Edward F Domino
Journal:  Neuropsychopharmacology       Date:  2013-07-24       Impact factor: 7.853

6.  Effects of PDE4 pathway inhibition in rat experimental stroke.

Authors:  Fan Yang; Rachita K Sumbria; Dong Xue; Chuanhui Yu; Dan He; Shuo Liu; Annlia Paganini-Hill; Mark Fisher
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

Review 7.  Cysteinyl Leukotrienes as Potential Pharmacological Targets for Cerebral Diseases.

Authors:  Paolo Gelosa; Francesca Colazzo; Elena Tremoli; Luigi Sironi; Laura Castiglioni
Journal:  Mediators Inflamm       Date:  2017-05-10       Impact factor: 4.711

8.  Neuroprotective Effects of Salidroside on Cerebral Ischemia/Reperfusion-Induced Behavioral Impairment Involves the Dopaminergic System.

Authors:  Zhi-Feng Zhong; Jing Han; Ji-Zhou Zhang; Qing Xiao; Jing-Yan Chen; Kai Zhang; Juan Hu; Li-Dian Chen
Journal:  Front Pharmacol       Date:  2019-12-13       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.